The RSA Group Appoints Andy Theodorou as Partner
Appointment recognises Andy’s decade-long contribution to RSA, including team development, scientific expertise and role in building the firm’s West Coast business.
Refreshed website provides a clearer platform for RSA’s executive search, fractional and interim leadership expertise as the firm enters its next phase of growth.
Andy Theodorou Appointed as Partner at The RSA Group
Hertfordshire, UK, 7 July 2026 – The RSA Group (“RSA”), the specialist executive search and advisory firm uniting the best people in innovation and life sciences, today announces the appointment of Andy Theodorou as Partner, effective immediately, alongside the launch of its refreshed website.
Andy, previously Senior Consultant, joined RSA in 2015 and brings more than 25 years’ executive search experience, combined with a deep scientific background and a longstanding understanding of biotechnology clients and their leadership needs. A qualified neuroscientist with a BSc and PhD in Pharmacology, Andy has advised on senior appointments across global pharma, biotech, speciality pharma, medtech, and academic research organisations.
Over a Decade of Contribution and West Coast Expansion
His areas of expertise span discovery research, clinical development, regulatory affairs, market access, medical, commercial, and general management. Andy’s appointment recognises his contribution to RSA over the past decade, including his dedication to developing the team and his key role in building the firm’s West Coast business.
A Trusted Adviser in Critical Leadership Choices
“Andy has made an outstanding contribution to RSA over the past decade, not only through the quality of his client work, but through his support for colleagues, commitment to developing our team, and role in building our West Coast business,” said Nick Stephens, Executive Chairman of The RSA Group.
“His scientific depth and understanding of biotechnology clients make him a trusted adviser at moments when leadership choices matter most. Andy and I will continue working closely together as RSA builds on its momentum and enters an important next phase of growth.”
A Relationship-Led Approach to Life Science Executive Search
Andy Theodorou, Partner at The RSA Group, commented: “RSA has always combined specialist sector expertise with a practical, relationship-led understanding of what clients need at critical moments. I am proud to take on this role and to continue working with colleagues and clients to help life sciences organisations build the leadership teams and specialist capability needed to advance their science, strengthen their organisations, and deliver long-term impact.”
Aligning Leadership Sourcing with Digital Launch
The appointment comes as RSA launches its refreshed website, designed to better reflect the firm’s established strengths in executive search and fractional and interim leadership, and to make it easier for clients, candidates, and partners to understand its services, team, track record, and insights.
Serving the life sciences community since 1981, RSA works with biotech, pharma, medtech, diagnostics, CDMO, and health technology companies to identify and secure board, leadership, and strategic talent. The refreshed website provides a clearer platform for engagement as RSA continues to support clients through critical leadership and organisational inflection points.
Media Contacts
The RSA Group
Lois Stephens
Tel: +44 (0)20 3818 8830
Email: hq@theRSAgroup.com
About The RSA Group
The RSA Group is a specialist executive search firm in global life sciences. Providing a unique combination of executive search and fractional and interim leadership, the firm supports clients through data-driven due diligence and evidence-led assessment. Its Proof of Candidate® approach is based on evidence and in-depth comparative analysis, helping clients make better hiring decisions.
Since 1981, RSA’s consultants have drawn on their wealth of executive search and industry experience to deliver focused solutions for clients across biotech, specialty pharma, rare disease, generics, CDMO, PE and VC backed businesses, and health technology. Large enough to be global and small enough to remain local, RSA operates where its clients are. To learn more about The RSA Group, visit www.thersagroup.com.
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 40 40" xmlns="http://www.w3.org/2000/svg"><path d="M 40 2.857 L 40 37.143 C 40 37.901 39.699 38.627 39.163 39.163 C 38.627 39.699 37.901 40 37.143 40 L 2.857 40 C 2.099 40 1.373 39.699 0.837 39.163 C 0.301 38.627 0 37.901 0 37.143 L 0 2.857 C 0 2.099 0.301 1.373 0.837 0.837 C 1.373 0.301 2.099 0 2.857 0 L 37.143 0 C 37.901 0 38.627 0.301 39.163 0.837 C 39.699 1.373 40 2.099 40 2.857 Z M 11.429 14.286 L 5.714 14.286 L 5.714 34.286 L 11.429 34.286 Z M 12.143 8.571 C 12.143 7.624 11.767 6.716 11.097 6.046 C 10.427 5.376 9.519 5 8.571 5 C 7.624 5 6.716 5.376 6.046 6.046 C 5.376 6.716 5 7.624 5 8.571 C 5 9.519 5.376 10.427 6.046 11.097 C 6.716 11.767 7.624 12.143 8.571 12.143 C 9.519 12.143 10.427 11.767 11.097 11.097 C 11.767 10.427 12.143 9.519 12.143 8.571 Z M 34.286 23.686 C 34.286 17.4 32.2 13.714 26.114 13.714 C 24.844 13.714 23.593 14.027 22.472 14.625 C 21.351 15.223 20.394 16.088 19.686 17.143 L 19.686 14.286 L 14.286 14.286 L 14.286 34.286 L 20 34.286 L 20 24.943 C 19.925 24.265 19.99 23.578 20.192 22.927 C 20.394 22.275 20.727 21.672 21.172 21.154 C 21.617 20.637 22.164 20.217 22.778 19.92 C 23.392 19.623 24.061 19.456 24.743 19.429 C 28.057 19.429 28.572 22.686 28.572 24.943 L 28.572 34.286 L 34.286 34.286 Z" fill="rgb(10, 102, 194)" height="40px" id="rtqO1NEDt" width="40px"/></svg>)
